PDB-code
Browse PDE entries (page 22 of 31)
First 18 19 20 PreviousLast26 25 24 Next| # | Species | PDE Type | PDB | Chain | Alternate Model | Ligand | Details | File |
|---|---|---|---|---|---|---|---|---|
 | Human | PDE4D | 1y2e | A | B | 1-(4-AMINOPHENYL)-3,5-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER |  | |
| Human | PDE4D | 1y2e | B | A | 1-(4-AMINOPHENYL)-3,5-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | |
| Human | PDE4D | 1y2e | B | B | 1-(4-AMINOPHENYL)-3,5-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | |
| Human | PDE4D | 1y2k | A | A | 3,5-DIMETHYL-1-(3-NITROPHENYL)-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | |
| Human | PDE4D | 1y2k | A | B | 3,5-DIMETHYL-1-(3-NITROPHENYL)-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | |
| Human | PDE4D | 1y2k | B | A | 3,5-DIMETHYL-1-(3-NITROPHENYL)-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | |
| Human | PDE4D | 1y2k | B | B | 3,5-DIMETHYL-1-(3-NITROPHENYL)-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | |
| Human | PDE4D | 1zkn | A | 3-ISOBUTYL-1-METHYLXANTHINE | | ||
| Human | PDE4D | 1zkn | B | 3-ISOBUTYL-1-METHYLXANTHINE | | ||
| Human | PDE4D | 1zkn | C | 3-ISOBUTYL-1-METHYLXANTHINE | | ||
| Human | PDE4D | 1zkn | D | 3-ISOBUTYL-1-METHYLXANTHINE | | ||
| Human | PDE4D | 2fm0 | A | (S)-3-(2-(3-CYCLOPROPOXY-4-(DIFLUOROMETHOXY)PHENYL)-2-(5-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)THIAZOL-2-YL)ETHYL)PYRIDINE1-OXIDE | | ||
| Human | PDE4D | 2fm0 | B | (S)-3-(2-(3-CYCLOPROPOXY-4-(DIFLUOROMETHOXY)PHENYL)-2-(5-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)THIAZOL-2-YL)ETHYL)PYRIDINE1-OXIDE | | ||
| Human | PDE4D | 2fm0 | C | (S)-3-(2-(3-CYCLOPROPOXY-4-(DIFLUOROMETHOXY)PHENYL)-2-(5-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)THIAZOL-2-YL)ETHYL)PYRIDINE1-OXIDE | | ||
| Human | PDE4D | 2fm0 | D | (S)-3-(2-(3-CYCLOPROPOXY-4-(DIFLUOROMETHOXY)PHENYL)-2-(5-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)THIAZOL-2-YL)ETHYL)PYRIDINE1-OXIDE | | ||
| Human | PDE4D | 2fm5 | A | (R)-3-(2-(3-CYCLOPROPOXY-4-(DIFLUOROMETHOXY)PHENYL)-2-(5-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)THIAZOL-2-YL)ETHYL)PYRIDINE1-OXIDE | | ||
| Human | PDE4D | 2fm5 | B | (R)-3-(2-(3-CYCLOPROPOXY-4-(DIFLUOROMETHOXY)PHENYL)-2-(5-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)THIAZOL-2-YL)ETHYL)PYRIDINE1-OXIDE | | ||
| Human | PDE4D | 2fm5 | C | (R)-3-(2-(3-CYCLOPROPOXY-4-(DIFLUOROMETHOXY)PHENYL)-2-(5-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)THIAZOL-2-YL)ETHYL)PYRIDINE1-OXIDE | | ||
| Human | PDE4D | 2fm5 | D | (R)-3-(2-(3-CYCLOPROPOXY-4-(DIFLUOROMETHOXY)PHENYL)-2-(5-(1,1,1,3,3,3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL)THIAZOL-2-YL)ETHYL)PYRIDINE1-OXIDE | | ||
| Human | PDE4D | 2pw3 | A | ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE | | ||
| Human | PDE4D | 2pw3 | B | ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE | | ||
| Human | PDE4D | 2qyn | A | 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoicacid | | ||
| Human | PDE4D | 2qyn | B | 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoicacid | | ||
| Human | PDE4D | 3g4g | A | 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | | ||
| Human | PDE4D | 3g4g | B | 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | | ||
| Human | PDE4D | 3g4g | C | 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | | ||
| Human | PDE4D | 3g4g | D | 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | | ||
| Human | PDE4D | 3g4i | A | 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | | ||
| Human | PDE4D | 3g4i | B | 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | | ||
| Human | PDE4D | 3g4i | C | 1-(3-nitrophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | |
This research was performed as part of the "Phosphodiesterase inhibitors for neglected parasitic diseases" (PDE4NPD) programme, which is supported by the European Union 7th Framework Program (FP7/2007-2013) under grant agreement n° 602666.
